Skip to main content
Advertisement
  • Neurology.org
  • Journals
    • Neurology
    • Clinical Practice
    • Education
    • Genetics
    • Neuroimmunology & Neuroinflammation
  • Online Sections
    • Neurology Video Journal Club
    • Diversity, Equity, & Inclusion (DEI)
    • Neurology: Clinical Practice Accelerator
    • Practice Buzz
    • Practice Current
    • Residents & Fellows
    • Without Borders
  • Collections
    • COVID-19
    • Disputes & Debates
    • Health Disparities
    • Infographics
    • Neurology Future Forecasting Series
    • Null Hypothesis
    • Patient Pages
    • Topics A-Z
    • Translations
    • UDDA Revision Series
  • Podcast
  • CME
  • About
    • About the Journals
    • Contact Us
    • Editorial Board
  • Authors
    • Submit Manuscript
    • Author Center

Advanced Search

Main menu

  • Neurology.org
  • Journals
    • Neurology
    • Clinical Practice
    • Education
    • Genetics
    • Neuroimmunology & Neuroinflammation
  • Online Sections
    • Neurology Video Journal Club
    • Diversity, Equity, & Inclusion (DEI)
    • Neurology: Clinical Practice Accelerator
    • Practice Buzz
    • Practice Current
    • Residents & Fellows
    • Without Borders
  • Collections
    • COVID-19
    • Disputes & Debates
    • Health Disparities
    • Infographics
    • Neurology Future Forecasting Series
    • Null Hypothesis
    • Patient Pages
    • Topics A-Z
    • Translations
    • UDDA Revision Series
  • Podcast
  • CME
  • About
    • About the Journals
    • Contact Us
    • Editorial Board
  • Authors
    • Submit Manuscript
    • Author Center
  • Home
  • Latest Articles
  • Current Issue
  • Past Issues
  • Neurology Video Journal Club
  • Residents & Fellows

User menu

  • Subscribe
  • My Alerts
  • Log in

Search

  • Advanced search
Neurology
Home
The most widely read and highly cited peer-reviewed neurology journal
  • Subscribe
  • My Alerts
  • Log in
Site Logo
  • Home
  • Latest Articles
  • Current Issue
  • Past Issues
  • Neurology Video Journal Club
  • Residents & Fellows

Share

January 05, 2021; 96 (1) Article

Reliability of Outcome Measures in Clinical Trials in Secondary Progressive Multiple Sclerosis

View ORCID ProfileMarcus W. Koch, Jop Mostert, View ORCID ProfilePavle Repovic, James D. Bowen, Bernard Uitdehaag, Gary Cutter
First published October 26, 2020, DOI: https://doi.org/10.1212/WNL.0000000000011123
Marcus W. Koch
From the Departments of Clinical Neurosciences (M.W.K.) and Community Health Sciences (M.W.K.), University of Calgary, Canada;Department of Neurology (J.M.), Rijnstate Hospital, Arnhem, the Netherlands; Multiple Sclerosis Center (P.R., J.D.B.), Swedish Neuroscience Institute, Seattle, WA; Department of Neurology (B.U.), MS Center Amsterdam, Amsterdam University Medical Centers, the Netherlands; and Department of Biostatistics (G.C.), University of Alabama at Birmingham.
MD, PhD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Marcus W. Koch
Jop Mostert
From the Departments of Clinical Neurosciences (M.W.K.) and Community Health Sciences (M.W.K.), University of Calgary, Canada;Department of Neurology (J.M.), Rijnstate Hospital, Arnhem, the Netherlands; Multiple Sclerosis Center (P.R., J.D.B.), Swedish Neuroscience Institute, Seattle, WA; Department of Neurology (B.U.), MS Center Amsterdam, Amsterdam University Medical Centers, the Netherlands; and Department of Biostatistics (G.C.), University of Alabama at Birmingham.
MD, PhD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Pavle Repovic
From the Departments of Clinical Neurosciences (M.W.K.) and Community Health Sciences (M.W.K.), University of Calgary, Canada;Department of Neurology (J.M.), Rijnstate Hospital, Arnhem, the Netherlands; Multiple Sclerosis Center (P.R., J.D.B.), Swedish Neuroscience Institute, Seattle, WA; Department of Neurology (B.U.), MS Center Amsterdam, Amsterdam University Medical Centers, the Netherlands; and Department of Biostatistics (G.C.), University of Alabama at Birmingham.
MD, PhD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Pavle Repovic
James D. Bowen
From the Departments of Clinical Neurosciences (M.W.K.) and Community Health Sciences (M.W.K.), University of Calgary, Canada;Department of Neurology (J.M.), Rijnstate Hospital, Arnhem, the Netherlands; Multiple Sclerosis Center (P.R., J.D.B.), Swedish Neuroscience Institute, Seattle, WA; Department of Neurology (B.U.), MS Center Amsterdam, Amsterdam University Medical Centers, the Netherlands; and Department of Biostatistics (G.C.), University of Alabama at Birmingham.
MD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Bernard Uitdehaag
From the Departments of Clinical Neurosciences (M.W.K.) and Community Health Sciences (M.W.K.), University of Calgary, Canada;Department of Neurology (J.M.), Rijnstate Hospital, Arnhem, the Netherlands; Multiple Sclerosis Center (P.R., J.D.B.), Swedish Neuroscience Institute, Seattle, WA; Department of Neurology (B.U.), MS Center Amsterdam, Amsterdam University Medical Centers, the Netherlands; and Department of Biostatistics (G.C.), University of Alabama at Birmingham.
MD, PhD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Gary Cutter
From the Departments of Clinical Neurosciences (M.W.K.) and Community Health Sciences (M.W.K.), University of Calgary, Canada;Department of Neurology (J.M.), Rijnstate Hospital, Arnhem, the Netherlands; Multiple Sclerosis Center (P.R., J.D.B.), Swedish Neuroscience Institute, Seattle, WA; Department of Neurology (B.U.), MS Center Amsterdam, Amsterdam University Medical Centers, the Netherlands; and Department of Biostatistics (G.C.), University of Alabama at Birmingham.
PhD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Full PDF
Short Form
Citation
Reliability of Outcome Measures in Clinical Trials in Secondary Progressive Multiple Sclerosis
Marcus W. Koch, Jop Mostert, Pavle Repovic, James D. Bowen, Bernard Uitdehaag, Gary Cutter
Neurology Jan 2021, 96 (1) e111-e120; DOI: 10.1212/WNL.0000000000011123

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Permissions

Make Comment

See Comments

Downloads
320

Share

  • Article
  • Figures & Data
  • Info & Disclosures
Loading

This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.

Abstract

Objective To investigate the reliability of clinical outcomes in secondary progressive multiple sclerosis (SPMS) trials, we compared the frequency of progression and improvement events on different clinical outcome measures in the placebo arms of 2 large randomized controlled trial (RCT) datasets.

Methods Using original trial data from the placebo arms of IMPACT (International MS Secondary Progressive Avonex Controlled Trial) and ASCEND (A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Participants With Secondary Progressive Multiple Sclerosis), 2 large RCTs in SPMS, we compared disability progression and similarly defined improvement with and without 3- or 6-month confirmation on the outcome measures Expanded Disability Status Scale (EDSS), Timed 25-Foot Walk (T25FW), 9-Hole Peg Test (9HPT), and their combinations.

Results In both datasets, the EDSS showed the highest rates of improvement over time, and the smallest difference between progression and improvement rates, followed by the T25FW and the 9HPT. For the T25FW and 9HPT, improvement rates were fairly stable over time and remained at below or around the 10% level. For the EDSS, improvement rates increased in parallel with disability progression rates.

Conclusions All investigated outcome measures in SPMS showed some evidence of random variation and measurement error, the T25FW and 9HPT less so than the more established outcome EDSS. Our findings are relevant for the design and critical appraisal of trials in SPMS.

Glossary

9HPT=
9-Hole Peg Test;
ASCEND=
A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Participants With Secondary Progressive Multiple Sclerosis;
EDSS=
Expanded Disability Status Scale;
IMPACT=
International MS Secondary Progressive Avonex Controlled Trial;
MS=
multiple sclerosis;
MSFC=
Multiple Sclerosis Functional Composite;
MSOAC=
Multiple Sclerosis Outcome Assessment Consortium;
PPMS=
primary progressive multiple sclerosis;
RCT=
randomized controlled trial;
RRMS=
relapsing-remitting multiple sclerosis;
SPMS=
secondary progressive multiple sclerosis;
T25FW=
Timed 25-Foot Walk

Footnotes

  • Go to Neurology.org/N for full disclosures. Funding information and disclosures deemed relevant by the authors, if any, are provided at the end of the article.

  • Editorial, page 12

  • Received February 14, 2020.
  • Accepted in final form August 6, 2020.
  • © 2020 American Academy of Neurology
View Full Text

AAN Members

We have changed the login procedure to improve access between AAN.com and the Neurology journals. If you are experiencing issues, please log out of AAN.com and clear history and cookies. (For instructions by browser, please click the instruction pages below). After clearing, choose preferred Journal and select login for AAN Members. You will be redirected to a login page where you can log in with your AAN ID number and password. When you are returned to the Journal, your name should appear at the top right of the page.

Google Safari Microsoft Edge Firefox

Click here to login

AAN Non-Member Subscribers

Click here to login

Purchase access

For assistance, please contact:
AAN Members (800) 879-1960 or (612) 928-6000 (International)
Non-AAN Member subscribers (800) 638-3030 or (301) 223-2300 option 3, select 1 (international)

Sign Up
Information on how to subscribe to Neurology and Neurology: Clinical Practice can be found here 

Purchase
Individual access to articles is available through the Add to Cart option on the article page.  Access for 1 day (from the computer you are currently using) is US$ 39.00.  Pay-per-view content is for the use of the payee only, and content may not be further distributed by print or electronic means.  The payee may view, download, and/or print the article for his/her personal, scholarly, research, and educational use.  Distributing copies (electronic or otherwise) of the article is not allowed.

Letters: Rapid online correspondence

No comments have been published for this article.
Comment

REQUIREMENTS

You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.

Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.

If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.

Submission specifications:

  • Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
  • Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
  • Submit only on articles published within 6 months of issue date.
  • Do not be redundant. Read any comments already posted on the article prior to submission.
  • Submitted comments are subject to editing and editor review prior to posting.

More guidelines and information on Disputes & Debates

Compose Comment

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
NOTE: The first author must also be the corresponding author of the comment.
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Publishing Agreement
NOTE: All authors, besides the first/corresponding author, must complete a separate Publishing Agreement Form and provide via email to the editorial office before comments can be posted.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

You May Also be Interested in

Back to top
  • Article
    • Abstract
    • Glossary
    • Methods
    • Results
    • Discussion
    • Study Funding
    • Disclosure
    • Appendix Authors
    • Footnotes
    • References
  • Figures & Data
  • Info & Disclosures
Advertisement

Association Between Fluctuations in Blood Lipid Levels Over Time With Incident Alzheimer Disease and Alzheimer Disease–Related Dementias

Dr. Sevil Yaşar and Dr. Behnam Sabayan

► Watch

Related Articles

  • Has the Time Come to Revisit Our Standard Measures of Disability Progression in Multiple Sclerosis?

Topics Discussed

  • Multiple sclerosis
  • Clinical trials Methodology/study design

Alert Me

  • Alert me when eletters are published

Recommended articles

  • Article
    Comparative utility of disability progression measures in PPMS
    Analysis of the PROMiSe data set
    Marcus W. Koch, Gary R. Cutter, Gavin Giovannoni et al.
    Neurology: Neuroimmunology & Neuroinflammation, May 10, 2017
  • Articles
    The Multiple Sclerosis Functional Composite
    A clinically meaningful measure of disability
    Chris H. Polman, Richard A. Rudick et al.
    Neurology, April 26, 2010
  • Editorial
    Has the Time Come to Revisit Our Standard Measures of Disability Progression in Multiple Sclerosis?
    Tomas Kalincik, Maria Pia Sormani, Carmen Tur et al.
    Neurology, October 26, 2020
  • Article
    Alemtuzumab improves preexisting disability in active relapsing-remitting MS patients
    Gavin Giovannoni, Jeffrey A. Cohen, Alasdair J. Coles et al.
    Neurology, October 12, 2016
Neurology: 101 (13)

Articles

  • Ahead of Print
  • Current Issue
  • Past Issues
  • Popular Articles
  • Translations

About

  • About the Journals
  • Ethics Policies
  • Editors & Editorial Board
  • Contact Us
  • Advertise

Submit

  • Author Center
  • Submit a Manuscript
  • Information for Reviewers
  • AAN Guidelines
  • Permissions

Subscribers

  • Subscribe
  • Activate a Subscription
  • Sign up for eAlerts
  • RSS Feed
Site Logo
  • Visit neurology Template on Facebook
  • Follow neurology Template on Twitter
  • Visit Neurology on YouTube
  • Neurology
  • Neurology: Clinical Practice
  • Neurology: Education
  • Neurology: Genetics
  • Neurology: Neuroimmunology & Neuroinflammation
  • AAN.com
  • AANnews
  • Continuum
  • Brain & Life
  • Neurology Today

Wolters Kluwer Logo

Neurology | Print ISSN:0028-3878
Online ISSN:1526-632X

© 2023 American Academy of Neurology

  • Privacy Policy
  • Feedback
  • Advertise